Last $28.34 USD
Change Today 0.00 / 0.00%
Volume 0.0
PTKFY On Other Exchanges
Symbol
Exchange
Indonesia
Munich
OTC US
OTC US
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

kalbe farma pt-unspons adr (PTKFY) Snapshot

Open
$27.72
Previous Close
$28.34
Day High
$28.34
Day Low
$27.72
52 Week High
07/16/14 - $30.75
52 Week Low
12/30/13 - $19.32
Market Cap
6.6B
Average Volume 10 Days
360.4
EPS TTM
--
Shares Outstanding
234.4M
EX-Date
06/13/14
P/E TM
--
Dividend
$0.29
Dividend Yield
1.01%
Current Stock Chart for KALBE FARMA PT-UNSPONS ADR (PTKFY)

Related News

No related news articles were found.

kalbe farma pt-unspons adr (PTKFY) Related Businessweek News

No Related Businessweek News Found

kalbe farma pt-unspons adr (PTKFY) Details

PT Kalbe Farma Tbk., together with its subsidiaries, produces and develops pharmaceutical products. The company operates in four segments: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic and branded products, and licensed drugs in the areas of antibacterial, oncology, nutrition, gastroenterology, ophthalmology, and neurology that are distributed to hospitals and pharmacies. It also offers over-the-counter drugs, supplements and other preventive products, and energy drinks and healthy ready-to-drink products; and nutritionals products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elders, as well as for consumers with special medical needs. In addition, it distributes third party pharmaceuticals products, as well as trades raw materials and medical devices; and provides retail health services. Further, the company provides animal health products; and contract research services and resources, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies. PT Kalbe Farma Tbk. was founded in 1966 and is headquartered in Jakarta, Indonesia.

11,776 Employees
Last Reported Date: 07/25/14
Founded in 1966

kalbe farma pt-unspons adr (PTKFY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kalbe farma pt-unspons adr (PTKFY) Key Developments

Kalbe Eyeing Phapros Stake In 2015 IPO

PT Kalbe Farma Tbk (JKSE:KLBF) is reviewing the possibility of acquiring a stake in PT Phapros Tbk. Kalbe may acquire Phapros should Phapros hold its initial public offering in early 2015, said Vidjongtius, a Director and Corporate Secretary at Kalbe. “Fundamentally speaking, Phapros is a company that keeps growing,” Vidjongtius said, adding that Kalbe is ready to buy shares of Phapros via IPO or another means. “Kalbe will indeed hold a shareholder meeting for this plan,” he said.

Kalbe Farma to Invest $149 Million in Business Expansion

Kalbe Farma has revealed that it has earmarked up to IDR 1.7 trillion (USD 148.7 million) to invest in expansion activities this year.

PT Kalbe Farma Tbk Announces Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for 2014

PT Kalbe Farma Tbk announced earnings results for the first quarter ended March 31, 2014. For the period, the company announced net sales of IDR 4,067 billion, an increase of 16.5% compared to the first quarter of 2013 of IDR 3,490 billion. Operating profit grew by 11.8%. Net profit grew by 11.0% compared to first quarter of 2013. Lower net profit growth compared to sales growth mostly came from the lower gross profit margin on the back of Rupiah depreciation, as well as the slight increase in operating expenses. The company provided earnings guidance for 2014. For 2014, the company targets to achieve sales and earnings growth of 14% to 16%, earnings per share growth of 15% to 17%, excluding the impact from foreign exchange translation and capital expenditure budget of IDR 1.0 to IDR 1.2 trillion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTKFY:US $28.34 USD 0.00

PTKFY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTKFY.
View Industry Companies
 

Industry Analysis

PTKFY

Industry Average

Valuation PTKFY Industry Range
Price/Earnings 39.4x
Price/Sales 4.6x
Price/Book 9.5x
Price/Cash Flow 39.4x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALBE FARMA PT-UNSPONS ADR, please visit www.kalbe.co.id. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.